In contrast to the modest toxicity reported in early stage HER2-negative breast cancer patients treated with nintedanib plus paclitaxel [34], in our preclinical study we observed signs of toxicity in the advanced metastatic treatment setting with LM2–4 cell line, occurring relatively soon after starting therapy with the drug combination. Here, ERBB2 is linked to breast carcinoma.